Historically, exception points for hepatocellular carcinoma (HCC) led to higher transplant rates and lower waitlist mortality for HCC candidates compared to non-HCC candidates. As of October 2015, HCC candidates must wait 6 months after initial application to obtain exception points; the impact of this policy remains unstudied.
| INTRODUC TI ON
The Organ Procurement and Transplantation Network (OPTN) implemented a revised policy in October 2015 to modify the timing and maximum value of exception points for hepatocellular carcinoma (HCC) candidates on the deceased donor liver transplant (DDLT) waitlist.
1,2 Before the policy change, HCC candidates received exception points of 22 for the first 3 months after initial application, followed by exception points of 25 for the first 3-month extension, 28 for the second 3-month extension, and 29 for the third 3-month extension. 2 Since the October 2015 policy change, HCC
candidates are listed at their calculated MELD scores for the first 3 months after initial application and for the first 3-month extension.
2 Subsequently, they receive exception points of 28 for the second 3-month extension at 6 months and 29 for the third 3-month extension at 9 months. [1] [2] [3] The revised policy also reduces the maximum exception points for HCC candidates from 40 to 34.
1-3
Historically, HCC candidates have experienced a substantial advantage in deceased donor liver allocation with lower waitlist mortality/dropout within 1 year of listing compared to non-HCC candidates (11.5% vs 17.7%). 4 Our group previously showed that HCC candidates had 1.6-fold higher odds of transplant and 53%
lower odds of 90-day waitlist mortality/dropout. Prior to implementation of the revised policy, a simulation study conducted by Heimbach et al predicted that a 6-month delay in exception point allocation would equalize the transplant and mortality/dropout rates for those with and without HCC exceptions. 8 However, this delay might create a window in which candidates with rapidly progressive HCC, who may have poor posttransplant outcomes, are removed from the waitlist. 9 Therefore, the revised policy has the potential to increase the waitlist mortality or removal for HCC candidates, potentially overcorrecting the prior advantage and introducing a disadvantage for HCC candidates.
F I G U R E 1 Construction of the study population
To better understand the effectiveness of the revised allocation policy and to address the OPTN public comments proposal requesting early postimplementation analysis, 9 we conducted an analysis of prospectively maintained national registry data to estimate the association between HCC and DDLT, waitlist mortality/dropout before and after the policy change. In addition, we compared posttransplant outcomes for HCC DDLT recipients before and after implementation of the revised policy. 
| ME THODS

| Data source
| Study population
| Deceased-donor liver transplant
Candidates entered the study at the time of approval of their excep- To illustrate time to waitlist mortality/dropout graphically, we also estimated the cumulative incidence of waitlist mortality/dropout accounting for DDLT as a competing risk, as described by Coviello and Boggess. 
| Waitlist dropout
Waitlist dropout was defined as removal from the waitlist because of deteriorating condition or medical unsuitability. We estimated the association between waitlist dropout and HCC while accounting for the competing risk of transplantation and waitlist mortality using Fine and Gray method 14 with adjustment for age, sex, race, and aMELD. As described previously, we report the subhazard ratio (sHR) of waitlist dropout for 0-6 months, 6-24 months, and 0-24 months.
Similar to previous models, we tested the interaction between HCC and policy era to determine whether the risk of waitlist dropout for HCC patients changed under the new policy. We also estimated the cumulative incidence of waitlist dropout accounting for DDLT and waitlist mortality as a competing risk.
13
| Waitlist mortality
We repeated this analysis to estimate the association between waitlist mortality and HCC while accounting for the competing risk of transplantation and waitlist dropout before and after the policy change using Fine and Gray method 14 and adjusting for age, sex, race, and aMELD.
| Regional variations in DDLT and waitlist mortality/dropout
To illustrate the changes in DDLT rate and waitlist mortality/dropout incidence pre-and postpolicy by United Network for Organ Sharing (UNOS) regions, we repeated the analysis, stratified by region, and present the results in Figure 4 .
| All-cause graft failure
To determine whether posttransplant outcomes were affected by the delay in exception point allocation among HCC DDLT recipients under the new policy, we compared all-cause graft failure among HCC DDLT recipients pre-vs postpolicy change. Because the DDLT rate for HCC candidates within the first 6 months of their exception point approval decreased substantially following the policy change, median post-DDLT follow-up time in the postpolicy era was 8.8 months. As such, in our study of all-cause graft failure we censored all participants at 1 year posttransplant. We estimated the cumulative incidence of all-cause graft failure (defined as retransplant or death) within 1 year of transplantation for HCC DDLT recipients pre-and postpolicy using Kaplan-Meier methods. We estimated the association between all-cause graft failure and the policy change among HCC recipients using Cox proportional hazards regression, adjusting for recipient age, sex, race, and donor risk index (DRI).
| Statistical analysis
All statistical analyses were performed using Stata 14. 
| HCC and waitlist mortality/dropout
In both eras, waitlist mortality/dropout for HCC candidates was lower compared to non-HCC candidates within 6 months of study entry (prepolicy: 4.8% vs 7.6%; postpolicy: 4.9% vs 5.9%) and also within 24 months of study entry (prepolicy: 8.7% vs 14.1%; postpolicy: 9.3% vs 9.6%) ( Figure 3A) .
Prepolicy, the risk of waitlist mortality/dropout for HCC candidates was 41% lower within the first 6 months of study entry compared to non-HCC candidates with the same aMELD (asHR = 0.50 0.59 0.70 , P < .001).
HCC and non-HCC candidates had a similar risk of waitlist mortality/ dropout between 6 and 24 months poststudy entry (asHR = 0.68 0.94 1.29 , P = .7). Over the 24 months as a whole, HCC candidates had 37% lower risk of waitlist mortality/dropout compared to non-HCC candidates with the same aMELD (asHR = 0.54 0.63 0.73 , P < .001) (Table 3A) . (Table 3A) .
| HCC and waitlist dropout
Prepolicy, 2.2% of HCC candidates dropped out within 6 months of study entry, compared to 2.5% of non-HCC candidates. Postpolicy, 3.3% of HCC candidates dropped out within 6 months of study entry, compared to 1.8% of non-HCC candidates ( Figure 3B ). In both eras, more HCC candidates dropped out within 24 months of study entry compared to non-HCC candidates (prepolicy: 4.8% vs 4.6%; postpolicy: 5.8% vs 3.0%) ( Figure 3B ).
Prepolicy, the risk of waitlist dropout for HCC candidates was 27% lower within the first 6-months of study entry compared to 
| HCC and waitlist mortality
In both eras, waitlist mortality for HCC candidates was lower compared to non-HCC candidates within 6 months of study entry (prepolicy: 2.6% vs 5.1%; postpolicy: 1.6% vs 4.1%) and also within 24 months of study entry (prepolicy: 3.9% vs 9.5%; postpolicy: 3.5% vs 6.6%) ( Figure 3C ).
In both eras, HCC candidates and non-HCC candidates had a similar mortality risk. Prepolicy, the risk of waitlist mortality for HCC candidates was 51% lower within the first 6 months of study entry compared to non-HCC candidates with the same aMELD (asHR = 0.40 0.49 0.62 , P < .001). HCC and non-HCC candidates had a similar risk of waitlist mortality between 6 and 24 months poststudy entry (asHR = 0.48 0.74 1.17 , P = .2). Over the 24 months as a whole, HCC candidates had 48% lower risk of waitlist mortality compared to non-HCC candidates with the same aMELD (asHR = 0.43 0.52 0.64 , P < .001) (Table 3C) .
Postpolicy, the risk of waitlist mortality for HCC candidates was 54% lower within the first 6 months of study entry compared to non-HCC candidates with the same aMELD (asHR = 0.34 0.46 0.62 , P < .001). HCC and non-HCC candidates had a similar risk of waitlist mortality between 6 and 24 months poststudy entry (asHR = 0.52 0.78 1.17 , P = .2). Over the 24 months as a whole, HCC candidates had 47% lower risk of waitlist mortality compared to non-HCC candidates with same aMELD (asHR = 0.41 0.53 0.68 , P < .001) (Table 3C ).
| Regional variations in DDLT and waitlist mortality/dropout
Prepolicy, DDLT rate for HCC candidates was much higher compared to non-HCC candidates in all regions. Postpolicy, DDLT rate for HCC candidates was still higher compared to non-HCC candidates in all regions. However, the difference in DDLT rate between HCC and non-HCC candidates was attenuated in the postpolicy era compared to the prepolicy era. The reduction in DDLT rate from pre-to postpolicy era was statistically significant for all regions except region 1 and region 9 ( Figure 4A ).
F I G U R E 3
Cumulative incidence of (A) waitlist mortality/ dropout, (B) waitlist dropout, (C) waitlist mortality for hepatocellular carcinoma (HCC) (solid) and non-HCC (dash) candidates in prepolicy (blue) and postpolicy (red) era Prepolicy, HCC candidates had substantially lower incidence of mortality/dropout compared to non-HCC candidates in regions 1, 2, 3, 5, 7, and 9. Postpolicy, HCC and non-HCC candidates had comparable chance of waitlist mortality/dropout in all regions ( Figure 4B ).
| HCC and all-cause graft failure
Among HCC DDLT recipients, 1-year graft failure was 7.5% prepolicy and 5.9% postpolicy (log-rank P = .1). After adjusting for recipient age (splined at 40, 55, 75), race, sex, DRI (splined at 2.5), there was no evidence of association between the policy change and 1-year graft failure (aHR = 0.60 0.79 1.03 ; P = .1; Figure 5 ).
| D ISCUSS I ON
In this national study of waitlist and posttransplant outcomes in liver waitlist registrants, we found that the substantial allocation advantage to HCC candidates in the prepolicy era (aHR = 3.7 compared to non-HCC candidates) remained, albeit attenuated, in the postpolicy era (aHR = 2.2). Furthermore, although HCC candidates had a 37% lower risk of waitlist mortality/dropout in the prepolicy era (asHR = 0.63), they experienced a comparable risk of mortality/ dropout in the postpolicy era (asHR = 0.95) compared to non-HCC candidates with similar allocation priority. Both before and after the policy change, HCC candidates had substantially lower risk of waitlist mortality compared to non-HCC candidates (asHR = 0.5).
However, although the risk of dropout for HCC candidates was comparable to the risk for non-HCC candidates before the policy change (asHR = 0.8), it was substantially higher than the risk for non-HCC candidates after the policy change (asHR = 1.9).
This study explored the equity in organ allocation for waitlist candidates in the 2 years preceding the October 2015 policy change. Our findings that HCC candidates had a 37% lower risk of mortality/dropout because of the 3.7-fold greater DDLT rate compared to non-HCC candidates in the prepolicy era are consistent with previous findings of lower waitlist mortality/dropout and higher DDLT rate for HCC candidates. [4] [5] [6] [7] The present study extended previous work by comparing DDLT rate for HCC and non-HCC candidates with the same cMELD in the pre-and postpolicy eras. In the postpolicy era, for the first time ever, HCC candidates had lower rates of transplant compared to non-HCC candidates with the same cMELD score in the first 6 months after approval of their exception. However, after this 6-month period, HCC candidates had 11-fold higher rates of transplant compared to non-HCC candidates with the same cMELD, such that, overall, HCC candidates continued to experience higher transplant rates.
Our findings reinforce the results of simulation studies conducted prior to the 2015 policy change. Using a liver simulation TA B L E 3 (A) Waitlist mortality/dropout, (B) waitlist dropout, and (C) waitlist mortality for HCC vs non-HCC, prepolicy and postpolicy, accounting for competing risks (CR). Prepolicy, HCC candidates had substantially lower incidence of waitlist mortality/dropout (asHR = 0.59), dropout (asHR = 0.73) and mortality (asHR = 0.49) compared to non-HCC candidates at the same aMELD during the first 6 months after study entry, but comparable incidence of waitlist mortality/dropout, dropout, mortality at 6-24 months after study entry; Within the first 24 months overall, their mortality/dropout risk was substantially lower compared to non-HCC candidates (sHR = 0.63). Postpolicy, HCC and non-HCC candidates had similar incidence of waitlist mortality/dropout (sHR = 0.95). However, risk of dropout was higher for HCC candidates compared to non-HCC candidates in postpolicy era (sHR = 1.93) and similar posttransplant survival in each interval. 16 In studying the real-world effects of this 6-month delay in exception point allocation after implementation of the revised OPTN/UNOS policy, we have confirmed that the delay did, in fact, reduce the advantage HCC candidates previously experienced in access to DDLT, while maintaining a comparable risk of waitlist mortality/dropout for HCC candidates compared to their non-HCC counterparts.
Our study must be understood in the context of several limitations.
The hazard ratios for 6-24 months could be affected by survival bias, as they were estimated using only candidates who were not removed in first 6 months. We were able to study posttransplant outcomes only for the first 12 months following the implementation of the October 2015 revised liver policy regarding HCC exception points. Thus, it remains uncertain whether the patterns we identified in posttransplant outcomes will persist after 1 year. We also recognize the potential limitations of using registry-based data. OPTN data are gathered across hundreds of centers, potentially with varying degrees of quality control and different policies for checking and updating MELD scores.
Additionally, we adjusted for a limited number of covariates based on which factors were available in this registry; for instance, we were unable to adjust for factors such as pretransplant HCC treatment, as such data were not available. However, despite these limitations, national registries constitute the only comprehensive data source for studies of changes in organ allocation at the national level.
Despite the aforementioned limitations, our study also has several key strengths. To our knowledge, this is the first study of changes in DDLT, risk of waitlist mortality, and posttransplant outcomes in light of recent modifications to the exception point allocation policy for HCC candidates. The sample size of our study was large enough to provide sufficient power in the stratified analysis.
Other strengths include accounting for the dynamic nature of MELD and the use of competing risks methods to elucidate the relationship between allocation priority and waitlist mortality.
In conclusion, our findings suggest that allocation of DDLT remained higher for HCC candidates than non-HCC candidates with the same calculated MELD 2 years after the implementation of the 2015 revised liver allocation policy; although the magnitude of the difference in DDLT rate was attenuated in the postpolicy era. 
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